Evidence map›Paper›PMID 38409551›Full record

ArticleOncogene2024

Ubiquitin specific peptidase 38 epigenetically regulates KLF transcription factor 5 to augment malignant progression of lung adenocarcinoma.

Tao Zhang, Fei Su, Bofang Wang, Lixin Liu, Yongbin Lu, Hongxin Su, Ruijiang Ling, Peng Yue, Huanyu Dai, Tianning Yang and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 14 citations in OpenAlex.

  1. USP38 promotes breast cancer immune evasion and malignant progression by deubiquitinating and stabilizing PD-L1.Mammalian genome : official journal of the International Mammalian Genome Society · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Tao Zhang *Department of Oncology, The First Hospital of Lanzhou University, Lanzhou, Gansu, PR China.
Fei Su *Department of Oncology, The First Hospital of Lanzhou University, Lanzhou, Gansu, PR China. sufei19881216@163.com.ORCID 0000-0002-5498-6130
Bofang Wang *The second clinical medical college of Lanzhou University, Lanzhou, Gansu, PR China.
Lixin Liu *Department of Thoracic Surgery, The First Hospital of Lanzhou University, Lanzhou, Gansu, PR China.
Yongbin LuDepartment of Oncology, The First Hospital of Lanzhou University, Lanzhou, Gansu, PR China.
Hongxin SuDepartment of Radiotherapy, The First Hospital of Lanzhou University, Lanzhou, Gansu, PR China.
Ruijiang LingDepartment of Thoracic Surgery, The First Hospital of Lanzhou University, Lanzhou, Gansu, PR China.
Peng YueDepartment of Thoracic Surgery, The First Hospital of Lanzhou University, Lanzhou, Gansu, PR China.
Huanyu DaiDepartment of Oncology, The First Hospital of Lanzhou University, Lanzhou, Gansu, PR China.
Tianning YangDepartment of Oncology, The First Hospital of Lanzhou University, Lanzhou, Gansu, PR China.
Jingru YangDepartment of Oncology, The First Hospital of Lanzhou University, Lanzhou, Gansu, PR China.
Rui ChenDepartment of Oncology, The First Hospital of Lanzhou University, Lanzhou, Gansu, PR China.
Ruiyue WuThe First Clinical Medical College of Lanzhou University, Lanzhou, Gansu, PR China.
Kaili ZhuThe First Clinical Medical College of Lanzhou University, Lanzhou, Gansu, PR China.
Da ZhaoDepartment of Oncology, The First Hospital of Lanzhou University, Lanzhou, Gansu, PR China. zhaoda@lzu.edu.cn.ORCID 0000-0002-5029-4014
Xiaoming HouDepartment of Oncology, The First Hospital of Lanzhou University, Lanzhou, Gansu, PR China. houxiaoming19@163.com.ORCID 0000-0002-8521-749X
First Hospital of Lanzhou University · CNLanzhou University Second Hospital · CN

Funding

National Natural Science Foundation of China (National Science Foundation of China) 81802269National Natural Science Foundation of China (National Science Foundation of China) 82260518
6 · The paper itself

Abstract

Protein ubiquitination is a common post-translational modification and a critical mechanism for regulating protein stability. This study aimed to explore the role and potential molecular mechanism of ubiquitin-specific peptidase 38 (USP38) in the progression of lung adenocarcinoma (LUAD). USP38 expression was significantly higher in patients with LUAD than in their counterparts, and higher USP38 expression was closely associated with a worse prognosis. USP38 silencing suppresses the proliferation of LUAD cells in vitro and impedes the tumorigenic activity of cells in xenograft mouse models in vivo. Further, we found that USP38 affected the protein stability of transcription factor Krüppel-like factors 5 (KLF5) by inhibiting its degradation. Subsequent mechanistic investigations showed that the N-terminal of USP38 (residues 1-400aa) interacted with residues 1-200aa of KLF5, thereby stabilizing the KLF5 protein by deubiquitination. Moreover, we found that PIAS1-mediated SUMOylation of USP38 was promoted, whereas SENP2-mediated de-SUMOylation of USP38 suppressed the deubiquitination effects of USP38 on KLF5. Additionally, our results demonstrated that KLF5 overexpression restored the suppression of the malignant properties of LUAD cells by USP38 knockdown. SUMOylation of USP38 enhances the deubiquitination and stability of KLF5, thereby augmenting the malignant progression of LUAD.

Indexed as

Adenocarcinoma of LungTranscription FactorsAnimalsCell ProliferationHumansKruppel-Like Transcription FactorsMiceUbiquitinationUbiquitin-Specific ProteasesKLF5 protein, humanKruppel-Like Transcription FactorsTranscription FactorsUbiquitin-Specific ProteasesUSP38 protein, human

Identifiers

PMID38409551
OpenAlexW4392153656

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.